Trust Signals
Written by the FormBlends Medical Team. Reviewed against FDA-approved prescribing information for Ozempic (semaglutide injection), ICH Q1A(R2) stability guidelines, and peer-reviewed peptide stability literature. No manufacturer relationships. Updated 2026-05-29.
Key Takeaways
- The branded reference (Ozempic) is labeled for up to 56 days at or below 30 degrees Celsius after first use, but this was validated in Novo Nordisk's specific formulation, not in compounded vials.
- Compounding pharmacies typically advise a maximum of 24 to 48 hours outside refrigeration for compounded semaglutide because no equivalent stability study exists for their formulations.
- The two main degradation pathways at room temperature are peptide bond hydrolysis and asparagine/glutamine deamidation; both accelerate sharply above 25 degrees Celsius.
- Early degradation produces no visible change. A clear, colorless solution can have meaningfully reduced potency.
- Freezing is as dangerous as overheating: ice crystal formation disrupts tertiary structure and can cause irreversible aggregation upon thawing.
Direct Answer
Compound semaglutide should not stay out of the fridge for more than 24 to 48 hours, and only if the ambient temperature stays below 25 degrees Celsius. The branded equivalent (Ozempic) carries a 56-day room-temperature label, but that data applies to a validated manufacturer formulation, not to compounded vials with different excipients, concentrations, and no formal stability study.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: What the Data Actually Supports
- What Happens Chemically When It Sits Out
- Temperature-by-Time Risk Table
- What Most Pages Get Dangerously Wrong
- Why the Storage Rules Exist: The Degradation Chemistry
- Compound vs. Branded: Honest Stability Comparison
- Operational and Label Literacy: Reading a COA, Vetting a Pharmacy
- How Do I Store Compound Semaglutide During Travel?
- What Does Degraded Compound Semaglutide Look Like?
- FAQ
- Sources
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Branded Ozempic is stable up to 56 days at or below 30 degrees C after first use | Manufacturer stability study (ICH Q1A); reflected in FDA-approved labeling | Stable within window | High (for branded formulation only) |
| Compounded semaglutide shares the same room-temperature stability as Ozempic | Assumed by analogy; no independent compounded-formulation study publicly available | Unknown / not validated | Very Low |
| Peptide hydrolysis and deamidation accelerate meaningfully above 25 degrees C | Physical chemistry; established across GLP-1 analog and peptide literature | Accelerated degradation | High (mechanism level) |
| Freezing causes aggregation and potency loss in semaglutide | Reflected in FDA label; consistent with protein/peptide stability literature | Harmful | High |
| A 24 to 48 hour out-of-fridge limit for compounded vials is a safe rule | Conservative extrapolation from branded data; pharmacy practice consensus | Prudent minimum | Moderate (no RCT; rationale is sound) |
| Degraded semaglutide produces visible turbidity or color change | Mechanism-level expectation; validated for aggregated peptides generally | Late-stage indicator only | Moderate (early degradation is invisible) |
| Bacteriostatic water extends microbial safety of multi-dose vials | USP standards for benzyl alcohol as a preservative | Beneficial for microbial safety | High (does not address peptide stability) |
What Happens Chemically When It Sits Out
Semaglutide is a 31-amino-acid GLP-1 receptor agonist modified at two positions relative to native GLP-1: an Aib substitution at position 8 (protecting against DPP-4 cleavage) and a C18 fatty diacid chain attached via a linker at lysine-26 (enabling albumin binding and the long half-life of roughly 7 days in humans).
When stored above refrigerator temperature, three degradation pathways accelerate:
- Hydrolysis of peptide bonds: Water molecules attack amide bonds, fragmenting the chain. Rate increases roughly two to threefold per 10 degree Celsius rise in temperature (Arrhenius behavior). At 40 degrees C, the reaction proceeds meaningfully faster than at 20 degrees C.
- Deamidation of Asn and Gln residues: Asparagine and glutamine side chains convert to aspartate and glutamate, altering the charge and three-dimensional conformation of the peptide. This is particularly sensitive to pH as well as temperature.
- Aggregation: Heat causes partial unfolding, exposing hydrophobic regions that stick to each other. Aggregated peptide cannot bind the GLP-1 receptor and may also carry immunogenicity risk, though clinical significance of low-level aggregation in compounded vials has not been formally studied.
- Oxidation of the fatty acid chain: The linker and fatty acid side chain at K26 can undergo oxidative degradation, particularly in the presence of trace metals or dissolved oxygen, reducing albumin-binding affinity and therefore shortening effective half-life.
What this does NOT prove: Knowing the mechanism does not tell us the exact potency remaining in a specific compounded vial after 24 hours at 28 degrees C. That requires formulation-specific stability testing. The mechanism tells us the direction of change (always worse), not the magnitude.
Temperature-by-Time Risk Table
| Condition | Duration | Estimated Risk Level | Basis |
|---|---|---|---|
| Refrigerator, 2 to 8 degrees C | Up to pharmacy-labeled expiry | Low (intended storage) | Branded labeling; standard pharmaceutical cold-chain |
| Room temperature, below 25 degrees C | Up to 24 hours | Low to Moderate | Conservative extrapolation from branded 56-day data at 30 degrees C |
| Room temperature, below 25 degrees C | 24 to 72 hours | Moderate (compounded vials only; branded labeled safe) | Branded data exists; compounded formulation not validated |
| Room temperature, 25 to 30 degrees C | Over 24 hours | Moderate to High | Upper boundary of branded label; accelerated degradation kinetics |
| Above 30 degrees C (e.g., hot car, direct sun) | Any duration over a few hours | High | Outside branded label; thermodynamic acceleration of all degradation pathways |
| Freezing, below 0 degrees C | Any | High (discard vial) | Explicitly contraindicated in branded labeling; ice-crystal aggregation |
| Repeated temperature cycling (fridge, out, fridge, out) | Multiple cycles | Moderate to High (cumulative) | Each cycle adds thermal and mechanical stress; not independently studied for semaglutide |
What Most Pages Get Dangerously Wrong
The most common error: Dozens of blogs, medspa FAQs, and forum posts cite the Ozempic 56-day room-temperature label and apply it directly to compounded semaglutide. This is a formulation equivalence assumption, not a validated fact.
Here is what those pages omit:
1. Excipient composition differs. Ozempic's approved formulation contains disodium phosphate dihydrate, propylene glycol, and phenol as a preservative, in a fixed pH-buffered aqueous solution. Compounded vials may use bacteriostatic water, saline, or different buffer systems. pH strongly influences the rate of asparagine deamidation and peptide bond hydrolysis. A formulation at pH 7.4 instead of Ozempic's optimized pH will degrade faster even at the same temperature.
2. Concentration matters. Higher peptide concentrations increase the probability of intermolecular aggregation. Compounded vials often contain 2.5 mg/mL or 5 mg/mL in preparations that may differ from the 1.34 mg/mL in Ozempic pens. No concentration-specific stability data is publicly available for these preparations.
3. COA does not equal stability study. A certificate of analysis confirms the product was pure and correctly identified at the time of manufacture. It says nothing about how it degrades at room temperature over days or weeks. These are entirely different documents. A pharmacy providing only a COA has not answered the stability question.
4. Invisible early degradation. A solution that looks perfectly clear can have lost a meaningful fraction of its potency through deamidation or small-scale aggregation. Relying on visual inspection alone is not adequate quality control.
Why the Storage Rules Exist: The Degradation Chemistry
The rule "store between 2 and 8 degrees Celsius" is not arbitrary. It comes from the Arrhenius equation: reaction rate increases exponentially with temperature. For most peptide degradation reactions, a 10 degree Celsius rise approximately doubles to triples the reaction rate. Refrigerator storage at 4 degrees C is therefore not slightly better than room temperature at 22 degrees C; it is many times slower in terms of degradation rate.
The rule "do not freeze" exists because water expands on freezing, forming ice crystals that physically disrupt the folded peptide structure. When the vial thaws, the damaged peptide aggregates. Unlike hydrolysis products (which are small fragments), aggregates can trigger immune responses, though the clinical threshold for this in peptide injectables is not clearly defined in the literature for semaglutide specifically.
The rule "protect from light" (less consistently stated for semaglutide than for some other peptides, but generally applicable) exists because ultraviolet and visible light can catalyze oxidation of tryptophan and methionine residues, and can also generate reactive oxygen species in aqueous solution that attack the peptide backbone.
Understanding these mechanisms lets you make your own judgment: a vial that sat on a cool bedside table for 10 hours is a different situation from one that spent 4 hours in a hot mailbox in July.
Compound vs. Branded: Honest Stability Comparison
| Factor | Ozempic (branded) | Compounded Semaglutide | Winner |
|---|---|---|---|
| Room-temperature stability data | 56 days at or below 30 degrees C, manufacturer-validated | No independent validation; pharmacy-specific guidance varies | Ozempic |
| Formulation consistency | Fixed pH, preservative, excipients; every pen identical | Varies by pharmacy, diluent, and concentration | Ozempic |
| Cost per mg of semaglutide | High (list price thousands per month without insurance) | Substantially lower in most markets | Compound |
| Dose flexibility | Fixed pen doses (0.25, 0.5, 1, 2 mg) | Titratable; custom doses possible | Compound |
| Regulatory oversight | Full FDA NDA approval with GMP manufacturing | 503A/503B compounding pharmacy oversight; variable | Ozempic |
| Purity verification available to patient | Implied by NDA; batch testing by Novo Nordisk | COA from third-party lab (quality varies by pharmacy) | Ozempic (more reliable) |
| Travel convenience | Pre-filled pen; less risk of handling error | Multi-dose vial with syringe; more steps, more exposure risk | Ozempic |
Operational and Label Literacy: Reading a COA, Vetting a Pharmacy
What a real COA should show: Identity confirmation (HPLC or mass spectrometry showing the correct molecular weight and retention time for semaglutide), purity as a percentage (you want 98 percent or above for an injectable peptide), absence of residual solvents if applicable, and the lot number and test date. The COA should be from an accredited third-party laboratory, not the pharmacy itself.
What a COA does NOT show: Stability over time, room-temperature shelf life, or potency at the time you inject it weeks later.
Questions to ask your compounding pharmacy:
- What diluent was used, and what is the final pH of the solution?
- Do you have any stability data (not just a COA) for this specific formulation at room temperature?
- What is the beyond-use date (BUD), and how was it determined? (USP Chapter 797 sets default BUDs for compounded sterile preparations; a pharmacy following these standards will cite them.)
- Was this prepared in an ISO Class 5 environment?
Reconstitution note (lyophilized powder): Some compounded semaglutide ships as a lyophilized (freeze-dried) powder. Dry powder is substantially more stable at room temperature than reconstituted solution. Once you add bacteriostatic water, the clock starts on chemical stability. Use the solution within the timeframe stated by your pharmacy, keep it refrigerated between uses, and do not confuse the pre-reconstitution stability with post-reconstitution stability.
How Do I Store Compound Semaglutide During Travel?
Use a soft-sided insulated cooler (a medication travel case) with a gel ice pack or Phase Change Material (PCM) pack. Wrap the pack in a thin cloth so the vial does not make direct contact with frozen material; contact with a frozen surface can locally freeze the solution in the glass, causing the ice-crystal damage described above.
On planes, carry the vial in your carry-on bag, not checked luggage. Cargo holds can experience temperature extremes in either direction. TSA allows medically necessary injectables and cooling equipment through security; carrying a prescription or pharmacy label removes ambiguity at the checkpoint.
If you are crossing time zones and your injection schedule shifts by more than a day or two, the once-weekly dosing schedule of semaglutide provides some flexibility. Consult your prescribing clinician, not a storage guide, for protocol adjustments.
What Does Degraded Compound Semaglutide Look Like?
At room temperature and in normal conditions, semaglutide solution should be clear, colorless, and free of visible particles. Any of the following should prompt you to discard the vial and contact your pharmacy:
- Visible cloudiness or turbidity (sign of aggregation)
- Visible particulates, flakes, or floating material
- Yellow, amber, or brown discoloration (sign of oxidation or advanced degradation)
- Gel-like or viscous texture when drawing into the syringe
The critical limitation: these are late-stage, visually detectable signs. A peptide solution can lose a meaningful fraction of its potency through deamidation and small-scale oligomer formation while still appearing perfectly clear. You cannot quality-control compounded peptides by eye. The only real protection is proper storage from the start and using the product within the timeframe your pharmacy specifies.
FAQ
How long can compound semaglutide stay out of the fridge?
The FDA-approved branded reference (Ozempic) is labeled for up to 56 days at room temperature after first use, at or below 30 degrees Celsius. Compounded semaglutide vials carry no manufacturer-validated expiry for room-temperature storage, so most compounding pharmacies conservatively advise a maximum of 24 to 48 hours out of refrigeration as a safety margin.
What temperature is too hot for compound semaglutide?
Based on branded semaglutide labeling, storage above 30 degrees Celsius (86 degrees F) is considered outside safe limits. Higher temperatures accelerate peptide hydrolysis and aggregation. A car dashboard, mailbox in summer, or direct sunlight can easily exceed this, sometimes reaching 60 to 70 degrees Celsius, which would cause rapid degradation.
Can I leave my compound semaglutide vial out overnight?
A single overnight period (8 to 10 hours) at typical indoor room temperature below 25 degrees Celsius is unlikely to cause meaningful potency loss based on branded stability data. However, compounded vials lack formal stability studies, so returning the vial to the fridge promptly is the only defensible default.
Does compound semaglutide look different when it has degraded?
Early degradation is not visible. Advanced degradation may produce visible particulates, cloudiness, or a color shift from clear to yellow or brown. If you see any of these signs, discard the vial. Absence of visible changes does NOT confirm potency is intact.
How should I store compound semaglutide during travel?
Use an insulated travel cooler with an ice pack that does not directly contact the vial (freezing damages the peptide). Keep total time above 8 degrees Celsius and below 30 degrees Celsius as brief as possible. TSA allows insulin and similar injectables in carry-on bags with documentation; treat semaglutide the same way.
What happens chemically when semaglutide degrades at room temperature?
The primary degradation pathways are hydrolysis of peptide bonds (accelerated by heat and moisture), deamidation of asparagine and glutamine residues, and aggregation driven by partial unfolding. The fatty acid side chain at position 26 (the albumin-binding moiety) can also undergo oxidation. All of these reduce receptor-binding potency.
Is compound semaglutide stable the same way Ozempic is?
Not necessarily. Ozempic's 56-day room-temperature label is based on formal, manufacturer-funded stability studies in a validated formulation. Compounded semaglutide uses different buffers, diluents, and concentrations that have not been through the same stability validation, so the Ozempic label cannot be directly applied.
What does a certificate of analysis (COA) tell me about stability?
A COA confirms purity and identity at the time of manufacture. It does NOT provide ongoing stability data or room-temperature expiry information. To assess stability, you would need a separate stability study in ICH Q1A guideline format performed on the specific compounded formulation. Very few compounding pharmacies provide this.
Can freezing damage compound semaglutide?
Yes. Branded Ozempic labeling explicitly states do not freeze. Ice crystal formation during freezing can disrupt the tertiary structure of the peptide and cause aggregation upon thawing. A vial that has been frozen and thawed may appear normal but have reduced potency. Do not use a vial if you suspect it has been frozen.
How do I know if my compound semaglutide was stored correctly during shipping?
Reputable compounding pharmacies ship with cold packs and temperature indicators. Check whether the package included a chemical temperature indicator or data logger. If the cold pack is fully melted and the package is warm on arrival, contact the pharmacy before using the product.
What is the fridge storage temperature range for compound semaglutide?
Based on branded reference labeling, refrigerate between 2 and 8 degrees Celsius (36 to 46 degrees F). This slows hydrolysis and aggregation dramatically without reaching the freezing point that causes ice-crystal damage. Store toward the middle of the fridge, away from the freezer compartment and the door (which fluctuates most).
Does bacteriostatic water affect how long compound semaglutide stays stable?
Bacteriostatic water contains 0.9 percent benzyl alcohol, which inhibits microbial growth and extends safe multi-dose use compared to sterile water for injection. However, bacteriostatic water does not materially change the chemical degradation rate of the peptide itself. Microbial safety and peptide stability are two different concerns.
Sources
- Novo Nordisk. Ozempic (semaglutide) injection prescribing information, including storage conditions. U.S. FDA-approved labeling. Available at: DailyMed, National Library of Medicine.
- ICH Q1A(R2): Stability Testing of New Drug Substances and Drug Products. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2003.
- USP Chapter 797: Pharmaceutical Compounding, Sterile Preparations. United States Pharmacopeia. Current edition.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. (General peptide and protein degradation mechanisms including hydrolysis, deamidation, and aggregation.)
- Wan X, Farahani A, Pappas A. Deamidation of asparagine in peptides: a review. Pharmaceutical Research. General reference for deamidation kinetics and pH/temperature dependence.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. (503A and 503B compounding pharmacy regulatory framework.)
- Lau J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. (Describes the structural modifications at positions 8 and 26 including the fatty acid linker chemistry.)
- Kristensen NB, et al. Pharmacokinetics, efficacy, and safety of subcutaneous semaglutide. Supporting information for GLP-1 receptor binding and plasma half-life data. Published in clinical trial reports for SUSTAIN program, referenced in FDA review documents.